Dihydralazine, an antihypertensive drug used to manage high blood pressure, was developed in the mid-20th century and became widely used in clinical practice in the 1950s and 1960s. Its history is marked by its effectiveness in lowering blood pressure, particularly in severe or resistant hypertension, but also by the recognition of potential side effects such as reflex tachycardia and lupus-like syndrome, which led to careful monitoring during therapy. Dihydralazine is primarily used as part of combination antihypertensive regimens. Its development emphasized the need for ongoing safety observation and individualized dosing to optimize therapeutic benefits while minimizing adverse effects.
BRAND NAMES
Apresoline – one of the most widely recognized brands
Hydralazine – generic name often used as a brand in some countries
Hydralazine Hydrochloride – available in oral and injectable formulations.
MECHANISM OF ACTION
Dihydralazine is a direct-acting vasodilator that primarily acts on the arterial smooth muscle. It relaxes vascular smooth muscle by interfering with calcium metabolism and cellular signaling, which reduces vascular resistance and lowers systemic blood pressure. The resulting arterial vasodilation decreases afterload, improving cardiac output in patients with hypertension or heart failure.
PHARMACOKINETICS
Absorption
Dihydralazine is well absorbed after oral administration, with peak plasma concentrations typically reached within 30 minutes to 2 hours. Its oral bioavailability is variable due to first-pass hepatic metabolism, which can reduce systemic exposure in some individuals. Food has minimal effect on absorption, allowing the drug to be taken with or without meals.
Distribution
Dihydralazine has a moderate volume of distribution, approximately 0.6–0.8 L/kg, reflecting its distribution primarily into body water and vascular tissues.
Metabolism
Dihydralazine is extensively metabolized in the liver, primarily through acetylation, which is subject to genetic variability. Individuals can be classified as “slow” or “fast” acetylators, affecting the rate of drug clearance and systemic exposure. Metabolism produces inactive metabolites that are eventually excreted in the urine.
Elimination
Dihydralazine is primarily eliminated by the kidneys as metabolites, with only a small fraction excreted unchanged. The elimination half-life varies depending on the acetylator status of the individual, typically ranging from 3 to 7 hours.
PHARMACODYNAMICS
Dihydralazine acts as a direct-acting arterial vasodilator, reducing systemic vascular resistance and lowering blood pressure. By relaxing arterial smooth muscle, it decreases afterload, which can improve cardiac output in patients with hypertension or heart failure. Reflex activation of the sympathetic nervous system often occurs, resulting in increased heart rate and myocardial contractility, which is why it is frequently co-administered with beta-blockers to mitigate tachycardia.
ADMINISTRATION
Dihydralazine can be administered orally for the management of chronic hypertension or intravenously for acute hypertensive crises. Oral tablets are usually taken 2–4 times daily with or without food to maintain consistent blood levels, while IV administration is given slowly under cardiac monitoring to prevent excessive hypotension.
DOSAGE AND STRENGTH
dihydralazine is typically administered orally at 10–50 mg, 2–4 times daily, with the dose adjusted according to blood pressure response and patient tolerance. In acute hypertensive crises, intravenous doses of 5–20 mg may be given slowly under close monitoring and repeated as necessary.
DRUG INTERACTIONS
Dihydralazine can interact with several medications due to its vasodilatory effects and influence on the cardiovascular system. Other antihypertensives (e.g., beta-blockers, ACE inhibitors, diuretics) may have additive blood pressure-lowering effects, increasing the risk of hypotension. Concomitant use with sympathomimetic drugs (e.g., epinephrine, norepinephrine) may counteract its antihypertensive effect.
FOOD INTERACTIONS
Food has minimal impact on the absorption of dihydralazine, allowing the medication to be taken with or without meals. However, a consistent intake pattern is recommended to maintain stable blood pressure control. Certain dietary factors, such as excessive alcohol consumption, may enhance the hypotensive effects of dihydralazine and increase the risk of dizziness or fainting.
CONTRAINDICATIONS
It should be avoided in individuals with severe coronary artery disease or recent myocardial infarction, as excessive vasodilation and reflex tachycardia may worsen ischemia. The drug is also contraindicated in patients with mitral valve rheumatic heart disease due to potential changes in cardiac dynamics.
SIDE EFFECTS
Headache
Dizziness or lightheadedness
Palpitations or tachycardia
Nausea and vomiting
Fatigue or weakness
Reflex tachycardia
Hypotension.
OVER DOSAGE
Overdose of dihydralazine can lead to severe hypotension, tachycardia, headache,dizziness, and palpitations due to excessive vasodilation and reflex sympathetic activation. In rare cases, it may cause myocardial ischemia or angina, especially in patients with pre-existing heart disease.
TOXICITY
Dihydralazine toxicity primarily results from excessive vasodilation, leading to severe hypotension, reflex tachycardia, palpitations, and dizziness. In some cases, angina or myocardial ischemia may occur, especially in patients with pre-existing coronary artery disease. Chronic overuse can increase the risk of drug-induced lupus-like syndrome, characterized by fever, joint pain, and rash. Management of toxicity involves discontinuation of the drug, supportive care, intravenous fluids, and monitoring of cardiovascular status.
